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Abstract: Pancreatic cancer remains among the deadliest forms of cancer with a 5 year survival rate
less than 10%. With increasing numbers being observed, there is an urgent need to elucidate the
pathogenesis of pancreatic cancer. While both contribute to disease progression, neither genetic nor
environmental factors completely explain susceptibility or pathogenesis. Defining the links between
genetic and environmental events represents an opportunity to understand the pathogenesis of
pancreatic cancer. Epigenetics, the study of mitotically heritable changes in genome function without
a change in nucleotide sequence, is an emerging field of research in pancreatic cancer. The main
epigenetic mechanisms include DNA methylation, histone modifications and RNA interference, all of
which are altered by changes to the environment. Epigenetic mechanisms are being investigated to
clarify the underlying pathogenesis of pancreatic cancer including an increasing number of studies
examining the role as possible diagnostic and prognostic biomarkers. These mechanisms also provide
targets for promising new therapeutic approaches for this devastating malignancy.

Pancreatic cancer is among the most aggressive gastrointestinal cancers, difficult to treat either by
surgical intervention or conventional chemotherapy. Therefore, there is clearly a need to clarify the
underlying mechanisms and to develop novel therapies based on these mechanisms. In 2000, a model
for pancreatic cancer was presented based solely on genetic alterations [1]. In this model, pancreatic
cancer arises from multiple genetic alterations, starting with mutations that promote the constitutive
activation of KRAS (Kirsten Rat Sarcoma). However, it is now clear that mechanisms based purely on
genetic mutations do not reveal the whole story. For example, pancreatic cancers with identical genetic
alterations do not respond in a similar way to chemotherapy or show similar disease course.
Following the complete sequencing of the human genome in 2001 [2,3], our understanding of
disease pathogenesis significantly improved. Pathogenesis for most neoplastic or non-neoplastic
disorders cannot be solely explained by genetics or environmental factors. They both contribute to
susceptibility, initiation and progression of most diseases. In pancreatic cancer, a significant gap in
understanding the underlying processes regulating disease pathogenesis still exists. In this regard,
epigenetic mechanisms have emerged as key mechanisms that could address this gap. The term
epigenetics was originally described in the 1950s by Conrad Waddington to delineate changes in
phenotype with no change in genotype [4,5]. In the current view, epigenetics is the study of mitotically
heritable changes in the genome function without a change in the nucleotide sequence [6]. Recently,
epigenetic mechanisms have emerged as possible explanations for the differential individual behavior
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of pancreatic cancers. This Special Issue focuses on the role of epigenetics in pancreatic cancer which is
projected to be the second cause of cancer death by 2030.
The main epigenetic mechanisms can be grouped into three main categories—DNA methylation,
modifications to core histone proteins comprising the nucleosome and RNA interference.
By definition, epigenetic modifications are heritable and reversible through cell division [7].
In development, epigenetic modifications promote multipotent cells to differentiate into more
defined cell types, with new phenotypes transferred to daughter cells [8]. DNA methylation is
established by DNA methyltransferases (DNMTs), which include the maintenance DNMT1 and
the de novo methyltransferases DNMT3a/b and DNMT3L [9]. Conversely, DNA demethylation
can occur through both passive demethylation through inhibition of methylation and active
enzymatic-based demethylation.
Histone modifications occur mainly in the tail regions of the histones, and include acetylation,
methylation, phosphorylation, and ubiquitination amongst other modifications. Post-transcriptional
modifications to histone structures are usually kept in balance [10]. When the balance is distorted
in either way, it leads to gene overexpression or gene repression. Finally, RNA interference refers to
noncoding RNAs such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), which modulate
gene expression in a sequence specific fashion [11,12].
In this issue, recent advances in epigenetic mechanisms that control pancreatic carcinogenesis
and the potential for targeting these mechanisms for diagnostic or therapeutic purposes will be
discussed. This issue also includes reviews on the role of the nuclear structure and nutriepigenomics in
pancreatic cancer. In each article, authors provide insight regarding potential therapeutic opportunities
in targeting epigenetic mechanisms.
There are two main precursor lesions resulting in pancreatic ductal adenocarcinoma (PDAC)
formation—pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm
(IPMN). From a genetic mutation perspective, more than 90% of pancreatic cancer patients have gain
of function KRAS mutations, and tumor suppressor genes such as SMAD4 and p53, are frequently
inactivated. However, no clear correlation has been established between the genetic subtypes of
pancreatic cancer and these lesion types, nor the transcriptional subtypes more recently identified
including squamous, pancreatic progenitor, exocrine-like (ADEX) and immunogenic PDACs. This lack
of correlation highlights possible underlying epigenetic mechanisms. Hank and Liss review these
basic epigenetics mechanisms in pancreatic cancer. They summarize basic epigenetic mechanisms
that pertain to pancreatic cancer, including histone acetylation and deacetylation models, histone
methylation and bromodomain and extraterminal (BET) regulation. Recent advances in chromatin
regulation and the potential role of such regulation in PDAC pathogenesis are highlighted.
Cellular function is affected by chromatin control through several mechanisms, including
structural mechanisms. Disruption of the nuclear structure can have significant consequences that
contribute to oncogenesis. Preston and Faustino describe how the nuclear envelope plays a key role in
controlling chromatin processes that are crucial for regulating PDAC pathogenesis. They spotlight
three specific components of the nuclear envelope including the LINC (linker of nucleoskeleton and
cytoskeleton) complex, which structurally couples cytoskeleton to chromatin and facilitates gene
regulation, the nuclear lamina, which provides structural integrity to nucleus, and the nuclear pore
complex, which mediates bidirectional nucleocytoplasmic transport. In addition, they describe how
components of the nuclear pore complex—nucleoporins—are used as diagnostic markers in cancer.
While mortality rates of cancer are generally declining, pancreatic cancer is a notable exception,
likely due to late diagnosis and resistance to conventional treatments. Epigenetic mechanisms are
likely to contribute to these factors in pancreatic cancer. Hamdan and Johnsen review epigenetic
targets as potential treatment options for pancreatic cancer. They highlight inhibitors for BET proteins
and histone deacetylases (HDAC) that exert direct or synergistic effects with other chemotherapeutic
agents. They emphasize how mediating their effects on distal regulatory elements, BET and HDAC
inhibitors may be effective in PDAC treatment.
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In our current understanding of PDAC progression, there are two proposed models. The first
involves clonal evolution and suggests tumors are biologically homogenous, derived from the same
clone. The second model includes stem cells in which heterogeneity exists across tumor cells providing
a defined hierarchical structure within the tumor. Recent studies suggest both models contribute to
tumor heterogeneity. Zagorac, Garcia-Bermejo and Sainz describe the epigenetic landscape of cancer
stem cells. They provide a summary of the effects that DNA methylation, histone modifications and
miRNAs have on cancer stem cells. Moreover, they outline possible epigenetic therapies that target
these mechanisms in cancer stem cells.
There is a significant body of research on the association between nutrition and pancreatic cancer.
The study of nutrients and their effects on human health through epigenetic mechanisms is termed
Nutriepigenomics. However, how specific diets increase or decrease cancer risk is still unclear, as well
as the effects that diet has on underlying epigenetic mechanisms. Specific to PDAC, epidemiological
studies show folate levels, fruit/vegetable consumption, red meat consumption and saturated fat
can alter pancreatic carcinogenesis. Epigenetic mechanisms linked to diet include folate changes
that induce donation of methyl groups, and diallyl disulfide and sulforaphone inhibition of histone
deacetylase [13,14], which stimulate apoptosis and inhibit cell proliferation.
Understanding epigenetic dysregulation mechanisms will contribute to our efforts in early
diagnostic biomarker development, define predictive and prognostic biomarkers and identify new
therapeutic approaches in pancreatic cancer. Thompson and Bednar review the clinical aspects of
epigenetic changes in PDAC. They describe how genome wide assessment of changes in methylation
status gave rise to next generation diagnostic assays. Cohen et al. describe a parallel approach for the
testing of protein markers and circulating free DNA (cfDNA) with high specificity [15]. Epigenetic
changes, including ARID1A, MLL1, MLL2, and MLL3 mutations or altered DNA methyltransferase
1 expression, alter survival in patients with pancreatic cancer [16,17]. Thompson and Bednar also
describe the relationship between epigenetic mechanisms and pancreatic cancer diagnosis, prognosis
and survival.
In total, this issue makes a strong case for future studies and a better understanding of the
epigenetic mechanisms that regulate pancreatic cancer initiation and progression. Through continued
work in these areas, better prognostic and diagnostic markers will be identified, patient-specific
treatment options will be supported and novel combinations of epigenetic and nonepigenetic drugs
will be investigated.
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